Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111183

Cover Image

PUBLISHER: Data Bridge Market Research Private Limited | PRODUCT CODE: 1111183

NA Glioblastoma Multiforme Treatment Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 226 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Web Access (Single User License) - Read Only
USD 3500
Web Access (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

The glioblastoma multiforme treatment market is projected to register a substantial CAGR of 8.1% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2019, the base year of calculation is 2021 and the forecast period is 2022 to 2029.

Market Segmentation:

North America Glioblastoma Multiforme Treatment Market, By Type (Primary (De Novo), Secondary), Treatment (Surgery, Radiotherapy, Medications), Patient Type (Adult, Geriatric, Child), Drug Type (Generics, Branded), Route of Administratin (Parenteral, Oral, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Germany, France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, Rest of Europe, Japan, China, India, Australia, Singapore, South Korea, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Egypt, Israel, UAE, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the glioblastoma multiforme treatment market are:

Increasing prevalence of the disease

High incidence in emerging markets.

Market Players:

Some of the major players operating in the market are:

F. Hoffmann-La Roche AG

Amgen Inc.

Merck & Co., Inc.

Pfizer Inc.

Varian Medical Systems, Inc. (A subsidiary of Siemens Healthcare)

ZEISS International

Amneal Pharmaceuticals LLC

Elekta

Sun Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd.

Eckert & Ziegler

Accord Healthcare

Angiochem

ANI Pharmaceuticals, Inc.

Arbor Pharmaceuticals, LLC. (A Subsidiary of Azurity Pharmaceuticals, Inc.)

AstraZeneca

Cantex Pharmaceuticals, Inc.

CELON LABS

Diffusion Pharmaceuticals Inc.

EnGeneIC

ERC.SA.

Genenta science

Jazz Pharmaceuticals, Inc.

Loxo Oncology (A Subsidiary of Eli Lilly)

Novartis AG

VBL THERAPEUTICS

Viatris Inc.

Zydus Pharmaceuticals, Inc.,

TABLE OF CONTENTS

1 INTRODUCTION 53

  • 1.1 OBJECTIVES OF THE STUDY 53
  • 1.2 MARKET DEFINITION 53
  • 1.3 OVERVIEW OF NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET 53
  • 1.4 LIMITATIONS 55
  • 1.5 MARKETS COVERED 56

2 MARKET SEGMENTATION 59

  • 2.1 MARKETS COVERED 59
  • 2.2 GEOGRAPHICAL SCOPE 60
  • 2.3 YEARS CONSIDERED FOR THE STUDY 61
  • 2.4 CURRENCY AND PRICING 61
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
  • 2.6 MULTIVARIATE MODELLING 65
  • 2.7 TYPE LIFELINE CURVE 65
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
  • 2.9 DBMR MARKET POSITION GRID 67
  • 2.10 MARKET END USER COVERAGE GRID 68
  • 2.11 VENDOR SHARE ANALYSIS 69
  • 2.12 SECONDARY SOURCES 70
  • 2.13 ASSUMPTIONS 70

3 EXECUTIVE SUMMARY 71

4 PREMIUM INSIGHTS 75

  • 4.1 PESTEL 76
  • 4.2 PORTER'S FIVE FORCES MODEL 77

5 EPIDEMIOLOGY 78

6 PIPELINE ANALYSIS 80

7 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: REGULATORY SCENARIO 82

8 MARKET OVERVIEW 84

  • 8.1 DRIVERS 86
    • 8.1.1 GROWING PREVALENCE OF GLIOBLASTOMA MULTIFORME 86
    • 8.1.2 INCREASING RESEARCH AND DEVELOPMENT (R&D) 86
    • 8.1.3 PRESENCE OF A STRONG PIPELINE 87
    • 8.1.4 GROWING GERIATRIC POPULATION 88
  • 8.2 RESTRAINTS 89
    • 8.2.1 HIGH COST OF GLIOBLASTOMA MULTIFORME TREATMENT 89
    • 8.2.2 ADVERSE SIDE-EFFECTS OF GLIOBLASTOMA MULTIFORME TREATMENT 90
  • 8.3 OPPORTUNITIES 90
    • 8.3.1 INCREASING DRUG APPROVALS 90
    • 8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS 91
    • 8.3.3 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT 91
  • 8.4 CHALLENGES 92
    • 8.4.1 LACK OF NEW TREATMENT 92
    • 8.4.2 ADVERSE EFFECTS AND RISKS ASSOCIATED WITH CANCER TREATMENT DRUGS 92
    • 8.4.3 LACK OF EARLY DETECTION 93

9 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE 94

  • 9.1 OVERVIEW 95
  • 9.2 PRIMARY (DE NOVO) 98
  • 9.3 SECONDARY 98

10 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT 100

  • 10.1 OVERVIEW 101
  • 10.2 SURGERY 104
  • 10.3 RADIOTHERAPY 104
    • 10.3.1 BRACHYTHERAPY 105
    • 10.3.2 FRACTIONATED STEREOTACTIC RT (FSRT) 105
    • 10.3.3 CONFORMAL OR INTENSITY-MODULATED RT 105
    • 10.3.4 RADIOSURGERY 106
  • 10.4 MEDICATIONS 106
    • 10.4.1 TEMOZOLOMIDE 107
      • 10.4.1.1 ORAL 107
      • 10.4.1.1 INTRAVENOUS 107
    • 10.4.2 NITROSOUREAS DRUGS 107
      • 10.4.2.1 CARMUSTINE 108
        • 10.4.2.1.1 PARENTERAL 108
        • 10.4.2.1.2 IMPLANTABLE WAFERS 108
      • 10.4.2.2 LOMUSTINE 108
      • 10.4.2.3 NIMUSTINE 109
      • 10.4.2.4 FOTEMUSTINE 109
    • 10.4.3 TARGETED THERAPY 109
      • 10.4.3.1 BEVACIZUMAB 109
      • 10.4.3.2 OTHERS 109
    • 10.4.4 ANTI-EPILEPTICS 109
      • 10.4.4.1 LEVETIRACETAM 110
      • 10.4.4.2 PHENYTOIN 110
      • 10.4.4.3 CARBAMAZEPINE 110
    • 10.4.5 CORTICOSTEROIDS 110
      • 10.4.5.1 METHYLPREDNISOLONE 111
      • 10.4.5.2 PREDNISONE 111
      • 10.4.5.3 OTHERS 111

11 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE 112

  • 11.1 OVERVIEW 113
  • 11.2 ADULT 116
    • 11.2.1 MALE 116
    • 11.2.2 FEMALE 117
  • 11.3 GERIATRIC 117
    • 11.3.1 MALE 118
    • 11.3.2 FEMALE 118
  • 11.4 CHILD 118

12 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE 120

  • 12.1 OVERVIEW 121
  • 12.2 GENERICS 124
  • 12.3 BRANDED 124

13 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 126

  • 13.1 OVERVIEW 127
  • 13.2 PARENTERAL 130
  • 13.3 ORAL 130
    • 13.3.1 CAPSULES 131
    • 13.3.2 TABLETS 131
    • 13.3.3 POWDERS 131
  • 13.4 OTHERS 131

14 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER 133

  • 14.1 OVERVIEW 134
  • 14.2 HOSPITAL 137
  • 14.3 CLINICS 137
  • 14.4 HOME HEALTHCARE 138
  • 14.5 OTHERS 139

15 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL 140

  • 15.1 OVERVIEW 141
  • 15.2 HOSPITAL PHARMACY 144
  • 15.3 RETAIL PHARMACY 144
  • 15.4 ONLINE PHARMACY 145
  • 15.5 OTHERS 145

16 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION 147

  • 16.1 NORTH AMERICA 148
    • 16.1.1 U.S. 158
    • 16.1.2 CANADA 162
    • 16.1.3 MEXICO 166

17 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY LANDSCAPE 170

  • 17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 170

18 SWOT ANALYSIS 171

19 COMPANY PROFILE 172

  • 19.1 F.HOFFMAN-LA ROCHE 172
    • 19.1.1 COMPANY SNAPSHOT 172
    • 19.1.2 REVENUE ANALYSIS 172
    • 19.1.3 COMPANY SHARE ANALYSIS 173
    • 19.1.4 PRODUCT PORTFOLIO 173
    • 19.1.5 RECENT DEVELOPMENT 173
  • 19.2 AMGEN INC. 174
    • 19.2.1 COMPANY SNAPSHOT 174
    • 19.2.2 REVENUE ANALYSIS 174
    • 19.2.3 COMPANY SHARE ANALYSIS 175
    • 19.2.4 PRODUCT PORTFOLIO 175
    • 19.2.5 RECENT DEVELOPMENTS 175
      • 19.2.5.1 PRODUCT APPROVAL 175
  • 19.3 MERCK & CO., INC 176
    • 19.3.1 COMPANY SNAPSHOT 176
    • 19.3.2 REVENUE ANALYSIS 176
    • 19.3.3 COMPANY SHARE ANALYSIS 177
    • 19.3.4 PRODUCT PORTFOLIO 177
    • 19.3.5 RECENT DEVELOPMENTS 177
      • 19.3.5.1 STRATETIC COLLABORATION 177
      • 19.3.5.2 EVENTS 178
  • 19.4 PFIZER INC. 179
    • 19.4.1 COMPANY SNAPSHOT 179
    • 19.4.2 REVENUE ANALYSIS 179
    • 19.4.3 COMPANY SHARE ANALYSIS 180
    • 19.4.4 PRODUCT PORTFOLIO 180
    • 19.4.5 RECENT DEVELOPMENT 180
      • 19.4.5.1 MERGER 180
  • 19.5 VARIAN MEDICAL SYSTEMS, INC. (A SUBSIDIARY OF SIEMENS HEALTHCARE) 181
    • 19.5.1 COMPANY SNAPSHOT 181
    • 19.5.2 REVENUE ANALYSIS 181
    • 19.5.3 COMPANY SHARE ANALYSIS 182
    • 19.5.4 PRODUCT PORTFOLIO 182
    • 19.5.5 RECENT DEVELOPMENT 182
      • 19.5.5.1 PARTNERSHIP 182
      • 19.5.5.2 ACQUISITION 183
  • 19.6 ZEISS INTERNATIONAL 184
    • 19.6.1 COMPANY SNAPSHOT 184
    • 19.6.2 REVENUE ANALYSIS 184
    • 19.6.3 PRODUCT PORTFOLIO 185
    • 19.6.4 RECENT DEVELOPMENTS 185
      • 19.6.4.1 PRODUCT EXPANSION 185
  • 19.7 AMNEAL PHARMACEUTICALS LLC 186
    • 19.7.1 COMPANY SNAPSHOT 186
    • 19.7.2 REVENUE ANALYSIS 186
    • 19.7.3 PRODUCT PORTFOLIO 187
    • 19.7.4 RECENT DEVELOPMENTS 187
      • 19.7.4.1 EVENT 187
      • 19.7.4.2 LAUNCH 187
      • 19.7.4.3 ACQUISITION 188
  • 19.8 ELEKTA 189
    • 19.8.1 COMPANY SNAPSHOT 189
    • 19.8.2 REVENUE ANALYSIS 189
    • 19.8.3 PRODUCT PORTFOLIO 190
    • 19.8.4 RECENT DEVELOPMENTS 190
      • 19.8.4.1 PARTNERSHIP 190
  • 19.9 SUN PHARMACEUTICAL INDUSTRIES LTD 191
    • 19.9.1 COMPANY SNAPSHOT 191
    • 19.9.2 REVENUE ANALYSIS 191
    • 19.9.3 PRODUCT PORTFOLIO 192
    • 19.9.4 RECENT DEVELOPMENT 192
      • 19.9.4.1 AGREEMENT 192
  • 19.10 TEVA PHARMACEUTICAL INDUSTRIES LTD 193
    • 19.10.1 COMPANY SNAPSHOT 193
    • 19.10.2 REVENUE ANALYSIS 193
    • 19.10.3 PRODUCT PORTFOLIO 194
    • 19.10.4 RECENT DEVELOPMENT 194
  • 19.11 ECKERT & ZIEGLER 195
    • 19.11.1 COMPANY SNAPSHOT 195
    • 19.11.2 REVENUE ANALYSIS 195
    • 19.11.3 PRODUCT PORTFOLIO 196
    • 19.11.4 RECENT DEVELOPMENT 196
  • 19.12 ACCORD HEALTHCARE 197
    • 19.12.1 COMPANY SNAPSHOT 197
    • 19.12.2 PRODUCT PORTFOLIO 197
    • 19.12.3 RECENT DEVELOPMENT 197
  • 19.13 ANGIOCHEM 198
    • 19.13.1 COMPANY SNAPSHOT 198
    • 19.13.2 PRODUCT PORTFOLIO 198
    • 19.13.3 RECENT DEVELOPMENT 198
      • 19.13.3.1 AGREMEENT 198
  • 19.14 ANI PHARMACEUTICALS, INC. 199
    • 19.14.1 COMPANY SNAPSHOT 199
    • 19.14.2 REVENUE ANALYSIS 199
    • 19.14.3 PRODUCT PORTFOLIO 200
    • 19.14.4 RECENT DEVELOPMENTS 200
      • 19.14.4.1 ACQUISITION 200
  • 19.15 ARBOR PHARMACEUTICALS, LLC. A SUBSIDIARY OF AZURITY PHARMACEUTICALS, INC. 201
    • 19.15.1 COMPANY SNAPSHOT 201
    • 19.15.2 PRODUCT PORTFOLIO 201
    • 19.15.3 RECENT DEVELOPMENT 201
      • 19.15.3.1 ACQUISITION 201
      • 19.15.3.2 PRODUCT APPROVAL 202
  • 19.16 ASTRAZENECA 203
    • 19.16.1 COMPANY SNAPSHOT 203
    • 19.16.2 REVENUE ANALYSIS 203
    • 19.16.3 PRODUCT PORTFOLIO 204
    • 19.16.4 RECENT DEVELOPMENT 204
      • 19.16.4.1 AGREEMENT 204
  • 19.17 CANTEX PHARMACEUTICALS, INC. 205
    • 19.17.1 COMPANY SNAPSHOT 205
    • 19.17.2 PRODUCT PORTFOLIO 205
    • 19.17.3 RECENT DEVELOPMENT 205
  • 19.18 CELON LABS 206
    • 19.18.1 COMPANY SNAPSHOT 206
    • 19.18.2 PRODUCT PORTFOLIO 206
    • 19.18.3 RECENT DEVELOPMENT 206
  • 19.19 DIFFUSION PHARMACEUTICAL 207
    • 19.19.1 COMPANY SNAPSHOT 207
    • 19.19.2 SERVICES PORTFOLIO 207
    • 19.19.3 RECENT DEVELOPMENT 207
  • 19.20 ERC.SA 208
    • 19.20.1 COMPANY SNAPSHOT 208
    • 19.20.2 PRODUCT PORTFOLIO 208
    • 19.20.3 RECENT DEVELOPMENT 208
      • 19.20.3.1 PIPELINE UPDATE 208
  • 19.21 ENGENEIC 209
    • 19.21.1 COMPANY SNAPSHOT 209
    • 19.21.2 PRODUCT PORTFOLIO 209
    • 19.21.3 RECENT DEVELOPMENTS 209
      • 19.21.3.1 AWARDS 210
  • 19.22 GENENTA SCIENCE 211
    • 19.22.1 COMPANY SNAPSHOT 211
    • 19.22.2 PRODUCT PORTFOLIO 211
    • 19.22.3 RECENT DEVELOPMENT 211
      • 19.22.3.1 EVENT 211
  • 19.23 JAZZ PHARMACEUTICALS, INC. 212
    • 19.23.1 COMPANY SNAPSHOT 212
    • 19.23.2 REVENUE ANALYSIS 212
    • 19.23.3 PRODUCT PORTFOLIO 213
    • 19.23.4 RECENT DEVELOPMENT 213
      • 19.23.4.1 ACQUISITION 213
  • 19.24 LOXO ONCOLOGY (A SUBSIDIARY OF ELI LILLY) 214
  • 1924.1 COANY SNAPSHOT 214
    • 19.24.2 PRODUCT PORTFOLIO 214
    • 19.24.3 RECENT DEVELOPMENT 214
  • 19.25 NOVARTIS AG 215
    • 19.25.1 COMPANY SNAPSHOT 215
    • 19.25.2 REVENUE ANALYSIS 215
    • 19.25.3 PRODUCT PORTFOLIO 216
    • 19.25.4 RECENT DEVELOPMENT 216
  • 19.26 VBL THERAPEUTICS 217
    • 19.26.1 COMPANY SNAPSHOT 217
    • 19.26.2 PRODUCT PORTFOLIO 217
    • 19.26.3 RECENT DEVELOPMENT 217
      • 19.26.3.1 EVENT 217
      • 19.26.3.2 AWARD 218
  • 19.27 VIATRIS INC 219
    • 19.27.1 COMPANY SNAPSHOT 219
    • 19.27.2 REVENUE ANALYSIS 219
    • 19.27.3 PRODUCT PORTFOLIO 220
    • 19.27.4 RECENT DEVELOPMENT 220
      • 19.27.4.1 AGREEMENT 220

  • 19.28 ZYDUS PHARMACEUTICALS, INC. 221
    • 19.28.1 COMPANY SNAPSHOT 221
    • 19.28.2 PRODUCT PORTFOLIO 221
    • 19.28.3 RECENT DEVELOPMENTS 221

20 QUESTIONNAIRE 222

21 RELATED REPORTS 226

LIST OF TABLES

  • TABLE 1 PIPELINE ANALYSIS FOR GLIOBLASTOMA MULTIFORME TREATMENT MARKET 48
  • TABLE 2 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 65
  • TABLE 3 NORTH AMERICA PRIMARY (DE NOVO) IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 66
  • TABLE 4 NORTH AMERICA SECONDARY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 67
  • TABLE 5 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 71
  • TABLE 6 NORTH AMERICA SURGERY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 72
  • TABLE 7 NORTH AMERICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 73
  • TABLE 8 NORTH AMERICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 73
  • TABLE 9 NORTH AMERICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 74
  • TABLE 10 NORTH AMERICA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 75
  • TABLE 11 NORTH AMERICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 75
  • TABLE 12 NORTH AMERICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 76
  • TABLE 13 NORTH AMERICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 76
  • TABLE 14 NORTH AMERICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 77
  • TABLE 15 NORTH AMERICA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 78
  • TABLE 16 NORTH AMERICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 78
  • TABLE 17 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 83
  • TABLE 18 NORTH AMERICA ADULTS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 84
  • TABLE 19 NORTH AMERICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 84
  • TABLE 20 NORTH AMERICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 85
  • TABLE 21 NORTH AMERICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 86
  • TABLE 22 NORTH AMERICA CHILD IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 87
  • TABLE 23 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 91
  • TABLE 24 NORTH AMERICA GENERICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 92
  • TABLE 25 NORTH AMERICA BRANDED IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 93
  • TABLE 26 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 97
  • TABLE 27 NORTH AMERICA PARENTERAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 98
  • TABLE 28 NORTH AMERICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 99
  • TABLE 29 NORTH AMERICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 99
  • TABLE 30 NORTH AMERICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 100
  • TABLE 31 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 104
  • TABLE 32 NORTH AMERICA HOSPITAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 105
  • TABLE 33 NORTH AMERICA CLINICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 106
  • TABLE 34 NORTH AMERICA HOME HEALTHCARE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 106
  • TABLE 35 NORTH AMERICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 107
  • TABLE 36 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 111
  • TABLE 37 NORTH AMERICA HOSPITAL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 112
  • TABLE 38 NORTH AMERICA RETAIL PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 113
  • TABLE 39 NORTH AMERICA ONLINE PHARMACY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 113
  • TABLE 40 NORTH AMERICA OTHERS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 114
  • TABLE 41 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 121
  • TABLE 42 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 121
  • TABLE 43 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 121
  • TABLE 44 NORTH AMERICA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 121
  • TABLE 45 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 122
  • TABLE 46 NORTH AMERICA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 122
  • TABLE 47 NORTH AMERICA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 122
  • TABLE 48 NORTH AMERICA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 122
  • TABLE 49 NORTH AMERICA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 123
  • TABLE 50 NORTH AMERICA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 123
  • TABLE 51 NORTH AMERICA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 123
  • TABLE 52 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 123
  • TABLE 53 NORTH AMERICA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 123
  • TABLE 54 NORTH AMERICA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 55 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 56 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 124
  • TABLE 57 NORTH AMERICA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 124
  • TABLE 58 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 124
  • TABLE 59 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 125
  • TABLE 60 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 126
  • TABLE 61 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 126
  • TABLE 62 U.S. RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 126
  • TABLE 63 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 126
  • TABLE 64 U.S. TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 127
  • TABLE 65 U.S. NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 127
  • TABLE 66 U.S. CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 127
  • TABLE 67 U.S. TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 127
  • TABLE 68 U.S. ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 127
  • TABLE 69 U.S. CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 128
  • TABLE 70 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 71 U.S. ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 72 U.S. GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 73 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 74 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 129
  • TABLE 75 U.S. ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 129
  • TABLE 76 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 129
  • TABLE 77 U.S. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 129
  • TABLE 78 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 130
  • TABLE 79 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 130
  • TABLE 80 CANADA RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 130
  • TABLE 81 CANADA MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 130
  • TABLE 82 CANADA TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 83 CANADA NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 84 CANADA CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 85 CANADA TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 86 CANADA ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 131
  • TABLE 87 CANADA CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 132
  • TABLE 88 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 132
  • TABLE 89 CANADA ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 132
  • TABLE 90 CANADA GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 132
  • TABLE 91 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 132
  • TABLE 92 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 133
  • TABLE 93 CANADA ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 133
  • TABLE 94 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 133
  • TABLE 95 CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 133
  • TABLE 96 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 97 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 134
  • TABLE 98 MEXICO RADIOTHERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 134
  • TABLE 99 MEXICO MEDICATIONS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 134
  • TABLE 100 MEXICO TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 101 MEXICO NITROSOUREAS DRUGS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 102 MEXICO CARMUSTINE IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 103 MEXICO TARGETED THERAPY IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 104 MEXICO ANTI-EPILEPTICS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 135
  • TABLE 105 MEXICO CORTICOSTEROIDS IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 136
  • TABLE 106 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 107 MEXICO ADULT IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 108 MEXICO GERIATRIC IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 109 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION) 136
  • TABLE 110 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 137
  • TABLE 111 MEXICO ORAL IN GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 137
  • TABLE 112 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 137
  • TABLE 113 MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 137

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 26
  • FIGURE 2 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET : DATA TRIANGULATION 29
  • FIGURE 3 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DROC ANALYSIS 30
  • FIGURE 4 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 31
  • FIGURE 5 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 31
  • FIGURE 6 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MULTIVARIATE MODELLING 32
  • FIGURE 7 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 33
  • FIGURE 8 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: DBMR MARKET POSITION GRID 34
  • FIGURE 9 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: MARKET END USER COVERAGE GRID 35
  • FIGURE 10 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: VENDOR SHARE ANALYSIS 36
  • FIGURE 11 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SEGMENTATION 40
  • FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND ASIA-PACIFIC IS GROWING AT THE FASTEST PACE IN NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 41
  • FIGURE 13 INCREASE IN THE PREVALENCE OF GLIOBLASTOMA MULTIFORME AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 42
  • FIGURE 14 PRIMARY (DE NOVO) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET IN 2022 & 2029 42
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET 52
  • FIGURE 16 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2021 62
  • FIGURE 17 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION) 63
  • FIGURE 18 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, CAGR (2022-2029) 63
  • FIGURE 19 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE, LIFELINE CURVE 64
  • FIGURE 20 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2021 68
  • FIGURE 21 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION) 69
  • FIGURE 22 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, CAGR (2022-2029) 69
  • FIGURE 23 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT: BY TREATMENT, LIFELINE CURVE 70
  • FIGURE 24 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2021 80
  • FIGURE 25 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION) 81
  • FIGURE 26 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, CAGR (2022-2029) 81
  • FIGURE 27 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE 82
  • FIGURE 28 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2021 88
  • FIGURE 29 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION) 89
  • FIGURE 30 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029) 89
  • FIGURE 31 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE 90
  • FIGURE 32 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021 94
  • FIGURE 33 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION) 95
  • FIGURE 34 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029) 95
  • FIGURE 35 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 96
  • FIGURE 36 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2021 101
  • FIGURE 37 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION) 102
  • FIGURE 38 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, CAGR (2022-2029) 102
  • FIGURE 39 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY END USER, LIFELINE CURVE 103
  • FIGURE 40 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021 108
  • FIGURE 41 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 109
  • FIGURE 42 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 109
  • FIGURE 43 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 110
  • FIGURE 44 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: SNAPSHOT (2021) 116
  • FIGURE 45 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021) 118
  • FIGURE 46 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2022 & 2029) 118
  • FIGURE 47 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY COUNTRY (2021 & 2029) 119
  • FIGURE 48 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: BY TYPE (2022-2029) 119
  • FIGURE 49 NORTH AMERICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET: COMPANY SHARE 2021 (%) 137
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!